Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delia Voronca

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Addiction Science & Clinical Practice|December 2, 2024
Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorderGavin Bart, Kelly S Barth, Paulette Baukol, et al.
Addiction Science & Clinical Practice|April 10, 2024
Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorderGavin Bart, P Todd Korthuis, Julie M Donohue, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trialKiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, et al.
Therapeutic Advances in Ophthalmology|July 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDavid M Brown, David S Boyer, Diana V Do, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Addiction Science & Clinical Practice|December 2, 2024
Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorderGavin Bart, Kelly S Barth, Paulette Baukol, et al.
Addiction Science & Clinical Practice|April 10, 2024
Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorderGavin Bart, P Todd Korthuis, Julie M Donohue, et al.
Japanese Journal of Ophthalmology|December 26, 2025
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trialKiyoshi Suzuma, Toshinori Murata, Masahiko Shimura, et al.
Therapeutic Advances in Ophthalmology|July 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDavid M Brown, David S Boyer, Diana V Do, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
Pageof 2